Exelixis (EXEL) Capital Expenditures Growth (1y) (2011 - 2026)
Exelixis (EXEL) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 143.40% |
| 10 | Exelixis | 14.48 Bn | 13.70 Bn | 590.86 Mn | -48.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -48.88% |
| Jan 2, 2026 | -70.91% |
| Oct 3, 2025 | -81.92% |
| Jul 4, 2025 | -56.80% |
| Apr 4, 2025 | -69.54% |
| Jan 3, 2025 | -69.72% |
| Sep 27, 2024 | -12.55% |
| Jun 28, 2024 | 10.66% |
| Mar 29, 2024 | -19.40% |
| Dec 29, 2023 | 35.18% |
| Sep 29, 2023 | 85.86% |
| Jun 30, 2023 | -19.08% |
| Mar 31, 2023 | 114.37% |
| Dec 30, 2022 | -80.20% |
| Sep 30, 2022 | 117.62% |
| Jul 1, 2022 | -63.70% |
| Apr 1, 2022 | -58.63% |
| Dec 31, 2021 | 98.15% |
| Apr 2, 2021 | 357.85% |
| Apr 3, 2020 | 28.35% |